Provided herein are compositions, systems, kits, and methods for treating a patient with a thromboembolism by administering nanoconjugates comprising nanoparticles encapsulating and/or conjugated to: i) tissue-type plasminogen activator (tPA), and ii) at least one antioxidant enzyme selected from the group consisting of: superoxide dismutase, glutathione peroxidase, glutathione reductase, and a catalase.

Provided herein are compositions, systems, kits, and methods for treating a patient with a thromboembolism by administering nanoconjugates comprising nanoparticles encapsulating and/or conjugated to: i) tissue-type plasminogen activator (tPA), and ii) at least one antioxidant enzyme selected from the group consisting of: superoxide dismutase, glutathione peroxidase, glutathione reductase, and a catalase.

The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity.

The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity.

The present disclosure relates to dietary supplements, for improving dermatological health. In embodiments, the composition is comprised of D-Biotin, grape seed extract, superoxide dismutase, zinc, Vitamin C, Lactobacillus Plantarum, Lactobacillus Reuteri, Lactobacillus Rhamnosus, or combinations/sub-combinations thereof.

The present disclosure relates to dietary supplements, for improving dermatological health. In embodiments, the composition is comprised of D-Biotin, grape seed extract, superoxide dismutase, zinc, Vitamin C, Lactobacillus Plantarum, Lactobacillus Reuteri, Lactobacillus Rhamnosus, or combinations/sub-combinations thereof.

The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, which contains, as an active ingredient, a Bacillus amyloliquefaciens GF423 strain, a superoxide dismutase high-producing Bacillus amyloliquefaciens GF424 mutant strain, a superoxide dismutase (SOD) derived from one of these strains, or both the strain and the SOD. The superoxide dismutase derived from the Bacillus amyloliquefaciens GF423 strain (KCTC 13222BP), which is the active ingredient of the present invention, effectively suppresses or degrades reactive oxygen species, and thus has the effect of fundamentally preventing the causes of inflammatory bowel disease caused by reactive oxygen species. Therefore, the composition of the present invention may be developed into various products, including excellent drugs and health functional foods for preventing or treating inflammatory bowel disease.

The disclosure in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.

An oral product comprising nano-sized, heat tolerable, shelf stable peptides and enzymes. Once the peptides and enzymes are inside the body of a user, they dimerize the nucleic acids of viruses, bacteria and fungi. Thus, the peptides and enzymes are capable of inactivating the genome of pathogens, including without limitation, SARS-CoV-2 and Influenza A/CA/04/2009 (H1N1) virus.

The present invention is directed to methods for the treatment or prevention of oxidative stress in a cell, e.g., photoreceptor cell, and methods for the treatment and prevention of disorders associated therewith by the administration of an agent, e.g., a nucleic acid molecule, which increases the expression and/or activity of an antioxidant defense protein.